Myriad Genetics - 13 Year Dividend History | MYGN
Historical dividend payout and yield for Myriad Genetics (MYGN) since 2011. The current TTM dividend payout for Myriad Genetics (MYGN) as of April 25, 2024 is $0.00. The current dividend yield for Myriad Genetics as of April 25, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.686B |
$0.753B |
|
Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made significant progress in transition & expand the hereditary cancer market, diversify revenues by commercializing its new products, increase the company's international contribution by investing in large countries, gaining reimbursement for new products, increasing international RNA kit revenue and enhancing profitability. Its flagship product BRACAnalysis offers a comprehensive analysis of BRCA1 and BRCA2 genes to assess a woman's risk of hereditary breast and ovarian cancers. Its major products are myRisk Hereditary Cancer, myPlan Lung Cancer and molecular diagnostic test myPath Melanoma. It acquired Counsyl, Inc. The company has 2 operating units: Molecular diagnostic & Pharmaceutical and clinical services.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
